Benign neoplasm
MONDO:0005165A neoplasm which is characterized by the absence of morphologic features associated with malignancy (severe cytologic atypia, tumor cell necrosis, and high mitotic rate). Benign neoplasms remain confined to the original site of growth and do not metastasize to other anatomic sites.
Also known as: benign neoplasm, benign neoplasm (disease), neoplasm (disease), benign, benign tumor, benign tumour, benign unclassifiable tumor, benign unclassifiable tumour, cell type benign neoplasm
2001 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 914 trials in this tab.
-
Custom-Made cancer vaccine shows promise in advanced tumors
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…
Phase: NA • Sponsor: Fudan University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:04 UTC
-
New drug aims to stop nosebleeds in rare blood vessel disorder
Disease control Recruiting nowThis study tests an experimental drug called ATV-1601 in people with moderate to severe HHT, a condition that causes frequent nosebleeds and anemia. The trial has two parts: first, participants receive either the drug or a placebo to check safety and effectiveness; then, all elig…
Phase: PHASE1, PHASE2 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New Dual-Action antibody takes on advanced cancers
Disease control Recruiting nowThis study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New hope for advanced cancer: APR-1051 enters first human trial
Disease control Recruiting nowThis early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…
Phase: PHASE1 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a Dual-Action antibody outsmart resistant tumors?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…
Phase: PHASE1, PHASE2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New drug FOG-001 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New drug targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New drug SHR-4610 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New drug targets Hard-to-Treat cancers with MET gene change
Disease control Recruiting nowThis phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could simple Over-the-Counter drugs supercharge cancer immunotherapy?
Disease control Recruiting nowThis study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…
Phase: PHASE2 • Sponsor: Val Adams • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to boost immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…
Phase: PHASE1, PHASE2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill shows promise in early cancer trial
Disease control Recruiting nowThis early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug CS5007 targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …
Phase: PHASE1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on advanced cancers in first human test
Disease control Recruiting nowThis early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…
Phase: PHASE1 • Sponsor: Groovy Medicine (Hangzhou) Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug MRG007 enters early human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug targets cancer DNA in advanced tumors
Disease control Recruiting nowThis early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New Dual-Antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: Ottimo Pharma Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a pill turn on genes that stop cancer? new trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can sound waves replace the scalpel for breast tumors?
Disease control Recruiting nowThis trial tests a combined imaging and treatment method called HMIgFUS for breast tumors. The approach uses focused ultrasound waves to heat and destroy tumor tissue, while a special imaging technique monitors the process in real time by measuring tissue stiffness. The study inc…
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cancer drug BNT3214 enters human trials for advanced tumors
Disease control Recruiting nowThis study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for advanced cancer: first human trial of FP008 begins
Disease control Recruiting nowThis early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…
Phase: PHASE1 • Sponsor: Zhuhai Fapon Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug COM503 enters first human trial for advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called COM503, alone or with another drug zimberelimab, in 200 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is a first-in-human study, so effe…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New immune drug PHST001 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…
Phase: PHASE1 • Sponsor: Pheast Therapeutics • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for advanced tumors? first human trial of DS-3939a begins
Disease control Recruiting nowThis early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug MGC026 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowThis extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental injection targets tumors directly in new cancer trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…
Phase: PHASE1 • Sponsor: Vaxiion Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New shot could make cancer treatment easier for patients with advanced tumors
Disease control Recruiting nowThis study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental pill GS-1206 takes aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug DS1025a takes on advanced solid tumors in first human trial
Disease control Recruiting nowThis trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cancer drug MBS8(1V270) enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…
Phase: PHASE1 • Sponsor: MonTa Biosciences ApS • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat breast cancers
Disease control Recruiting nowThis early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a simple asthma drug prevent a dangerous immunotherapy side effect?
Disease control Recruiting nowThis study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New Triple-Action antibody takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New master trial aims to speed up cancer treatments for kids
Disease control Recruiting nowThis trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Wart war: vitamin D3 or acyclovir injections – which works better?
Disease control Recruiting nowThis study tests whether injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts can clear them. Forty people aged 12 and older with common, plantar, flat, or nail warts will receive injections every two weeks for up to four sessions. The main goal is to se…
Phase: PHASE4 • Sponsor: Riphah International University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo may help bladder cancer patients keep their bladder
Disease control Recruiting nowThis study tests whether two drugs, enfortumab vedotin and pembrolizumab, can control muscle-invasive bladder cancer without needing to remove the bladder. About 390 adults whose cancer hasn't spread outside the bladder will receive either the drug combo or standard chemoradiatio…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
Disease control AVAILABLEThis study offers access to a radioactive therapy called 131I-MIBG for people with neuroblastoma or pheochromocytoma that has returned or stopped responding to standard treatments. The therapy is designed to seek out and deliver radiation directly to tumor cells. Researchers are …
Sponsor: Northwell Health • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can an mRNA therapy supercharge the immune system against cancer?
Disease control Recruiting nowThis trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…
Phase: PHASE1, PHASE2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Zinc-Based compound fight cancer?
Disease control Recruiting nowThis trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…
Phase: PHASE1, PHASE2 • Sponsor: Vector Vitale LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new immunotherapy combo shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced cancer?
Disease control Recruiting nowThis trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Cancer-Killing virus trial launches for patients out of options
Disease control Recruiting nowThis Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…
Phase: PHASE1 • Sponsor: ViroMissile, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo aims to boost immune system against advanced cancers
Disease control Recruiting nowThis study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody GEN1079 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New pill targets HER2 cancers in phase 2 trial
Disease control Recruiting nowThis study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…
Phase: PHASE1, PHASE2 • Sponsor: Everest Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Tailor-Made vaccine aims to train immune system against cancer
Disease control Recruiting nowThis early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug BG-C477 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New pill shows promise for rare tumors in Mid-Stage trial
Disease control Recruiting nowThis phase 2 study tests belzutifan, a daily pill that blocks a protein called HIF-2α, in people with advanced rare cancers like pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain other solid tumors. The goal is to see if …
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets MTAP deletion
Disease control Recruiting nowThis phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.
Phase: PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control Recruiting nowThis study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…
Phase: PHASE1, PHASE2 • Sponsor: PharmaMar • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Personalized maintenance therapy: a smarter way to treat advanced cancer?
Disease control Recruiting nowThis phase II trial is testing whether continuing targeted therapy or immunotherapy based on a tumor's molecular profile can benefit patients with advanced solid tumors that have stopped responding to prior treatment. After an initial treatment period, patients whose disease is s…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for advanced cancer patients? early trial of ZE94-0605 begins
Disease control Recruiting nowThis early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…
Phase: EARLY_PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a new drug called ROSE12 help fight advanced solid tumors?
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug E303 enters human trials
Disease control Recruiting nowThis early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …
Phase: PHASE1 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a new pill shrink Hard-to-Treat tumors? a trial aims to find out
Disease control Recruiting nowThis phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…
Phase: PHASE3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
A new care pathway aims to get cancer surgery patients home safer and faster
Disease control Recruiting nowThis large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…
Phase: NA • Sponsor: Regional Specialist Hospital in Wroclaw • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Cancer drug adagrasib offers continued hope in rollover trial
Disease control Recruiting nowThis study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug targets stomach and pancreatic cancers in early trial
Disease control Recruiting nowThis study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…
Phase: PHASE1, PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could an AI-Designed pill take on Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…
Phase: PHASE1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a new antibody help the immune system fight advanced cancers?
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…
Phase: PHASE1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New cancer drug targets two proteins at once in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…
Phase: PHASE1 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…
Phase: PHASE1, PHASE2 • Sponsor: Alyssum Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…
Phase: PHASE1 • Sponsor: Duboce Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Breathing tube-free lung surgery tested for patients with fragile lungs
Disease control Recruiting nowThis trial tests whether a type of minimally invasive lung surgery that avoids inserting a breathing tube (non-intubated thoracoscopic surgery) can reduce complications in patients with impaired lung function. These patients often need ICU care after standard surgery because thei…
Phase: NA • Sponsor: The Second Hospital of Shandong University • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
In-Womb procedure aims to save babies from deadly brain malformation
Disease control Recruiting nowThis study tests a one-time procedure done before birth to treat a rare brain blood vessel problem called vein of Galen malformation. The treatment blocks abnormal blood flow while the baby is still in the womb, at or after 34 weeks of pregnancy. About 20 fetuses will be treated,…
Phase: NA • Sponsor: Darren Orbach • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New cancer drug enters early human testing for advanced solid tumors
Disease control Recruiting nowThis early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New study tests two techniques to cut blood loss during fibroid surgery
Disease control Recruiting nowThis study compares two methods to control bleeding during laparoscopic myomectomy (surgery to remove fibroids from the uterus). One method uses a temporary tourniquet to block blood flow, and the other injects a medicine called epinephrine into the uterus to narrow blood vessels…
Phase: NA • Sponsor: Minia University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental pill takes on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could less be more? trial tests reduced radiation and chemo after surgery for HPV-Linked throat cancer
Disease control Recruiting nowThis trial studies people with HPV-positive oropharynx cancer whose tumors can be surgically removed. After surgery, patients are grouped by risk: low-risk patients get no further treatment, intermediate-risk get a lower dose of radiation, and high-risk get lower-dose radiation p…
Phase: PHASE2 • Sponsor: Heath Skinner • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New study aims to find best dose of heart drug to heal painful baby birthmarks
Disease control Recruiting nowThis study looks at how well different starting doses of the oral drug propranolol heal ulcers in infantile hemangioma (a type of birthmark). About 40 children with ulcerated hemangiomas will receive either a standard or higher initial dose. The main goal is to see which dose lea…
Phase: PHASE2, PHASE3 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers? first human trial of AUBE00 begins
Disease control Recruiting nowThis early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers? early trial launches
Disease control Recruiting nowThis first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…
Phase: PHASE1 • Sponsor: CytomX Therapeutics • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental shot aims to rev up immune system against advanced cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the s…
Phase: PHASE1 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental drug PA5 targets arginine to starve advanced cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can steroids help cancer patients resume a promising therapy?
Disease control Recruiting nowThis study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can engineered red blood cells fight cancer? new trial launches
Disease control Recruiting nowThis early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…
Phase: EARLY_PHASE1 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…
Phase: PHASE1, PHASE2 • Sponsor: LARKSPUR BIOSCIENCES, INC. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThis study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…
Phase: PHASE2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for advanced cancer patients as experimental drug enters trials
Disease control Recruiting nowThis study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…
Phase: PHASE1, PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New pill shows promise against tough cancers in early trial
Disease control Recruiting nowThis study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a fir…
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can a simple chat with your pharmacist boost cancer pill adherence?
Disease control Recruiting nowThis study tests a program where clinical pharmacists provide personalized counseling to cancer patients taking oral anticancer drugs. The goal is to see if this support helps patients take their medication more consistently. Researchers will compare two groups of 80 patients eac…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New chemo injection targets tumors directly in early trial
Disease control Recruiting nowThis early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…
Phase: PHASE1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for advanced cancers? early trial of PYX-201 begins
Disease control Recruiting nowThis early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…
Phase: PHASE1 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo takes on tough tumors
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…
Phase: PHASE1 • Sponsor: CytomX Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental cancer combo enters early human testing
Disease control Recruiting nowThis early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cocktail of old drugs takes on advanced cancers
Disease control Recruiting nowThis Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…
Phase: PHASE2 • Sponsor: Sarcoma Oncology Research Center, LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer pill SNV1521 enters human testing
Disease control Recruiting nowThis early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.
Phase: PHASE1 • Sponsor: Synnovation Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New cancer antibody ONC-841 enters human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control Recruiting nowThis study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …
Phase: PHASE1, PHASE2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cancer drug enters human testing
Disease control Recruiting nowThis early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Recruiting nowThis study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cancer drug H1710 enters first human tests
Disease control Recruiting nowThis early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …
Phase: PHASE1 • Sponsor: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Fighting viruses take on advanced tumors in early trial
Disease control Recruiting nowThis phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare cancers: experimental drug ADCT-701 enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug OVV-01 injected into tumors shows promise in early trial
Disease control Recruiting nowThis early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…
Phase: PHASE1 • Sponsor: Joint Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug STP938 tested in patients with incurable cancers
Disease control Recruiting nowThis early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…
Phase: PHASE1 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer drug pelabresib gets Long-Term safety check in extension trial
Disease control Recruiting nowThis study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New plug device under study for aneurysms and other blood flow problems
Disease control Recruiting nowThis study is checking how well a device called the Cera Vascular Plug works and if it is safe. The plug is used to block blood flow in certain blood vessels to treat conditions like aneurysms, abnormal connections between arteries and veins, and other problems. About 132 adults …
Sponsor: Lifetech Scientific (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug AN8025 tested in patients with advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New radiation method targets tough tumors
Disease control Recruiting nowThis phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…
Phase: PHASE2 • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New heat therapy could replace surgery for Hormone-Fueled hypertension
Disease control Recruiting nowThis study compares two treatments for a condition called primary aldosteronism, where a small adrenal gland tumor causes high blood pressure. One treatment is laparoscopic surgery to remove the tumor; the other is radiofrequency ablation (RFA), which uses heat delivered through …
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Supercharged immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…
Phase: PHASE1, PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo shows promise for Hard-to-Treat stomach cancer
Disease control Recruiting nowThis study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …
Phase: PHASE2, PHASE3 • Sponsor: SUNHO(China)BioPharmaceutical CO., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising combo targets Hard-to-Treat childhood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…
Phase: PHASE1, PHASE2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New experimental drug HS-20108 enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…
Phase: PHASE1 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New experimental drug SIM0613 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Nanoparticle drug aims to wake up immune system against tumors
Disease control Recruiting nowThis study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…
Phase: PHASE1, PHASE2 • Sponsor: United Immunity, co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill targets Hard-to-Treat cancers with a specific gene mutation
Disease control Recruiting nowThis study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug INV-6452 targets Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat cancers? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…
Phase: PHASE1, PHASE2 • Sponsor: Crossignal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New particles aim to shrink fibroids without surgery
Disease control Recruiting nowThis study is testing Bearing nsPVA particles, used during a procedure called uterine artery embolization, to treat uterine fibroids in 100 women. The goal is to see if these particles safely block blood flow to fibroids, reducing symptoms like pain and heavy bleeding. Participan…
Sponsor: Merit Medical Systems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo aims to revive immunotherapy in resistant cancers
Disease control Recruiting nowThis early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…
Phase: PHASE1 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Chilling out to fight cancer: cold therapy meets immunotherapy in new trial
Disease control Recruiting nowThis early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New cancer drug HLX316 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a pill that blocks estrogen help fight rare uterine cancers?
Disease control Recruiting nowThis phase 2 trial is testing elacestrant, a pill that breaks down estrogen receptors, in 30 people with advanced uterine sarcomas that are fueled by estrogen. The goal is to see if the drug can shrink tumors or slow their growth. Participants must have tumors that strongly expre…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for advanced cancer: first human trial of ALK201 begins
Disease control Recruiting nowThis study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Electric shock therapy may shrink blood vessel birthmarks
Disease control Recruiting nowThis study is testing a treatment called electrosclerotherapy for people with low-flow venous malformations (abnormal blood vessels present from birth). The goal is to shrink the malformation by at least 30% and reduce pain. About 65 participants will receive the treatment and be…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New Antibody-Drug conjugate targets advanced cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug, QLS5212, in 100 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find …
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New gene therapy targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New radiation approach aims to stop brain tumor regrowth
Disease control Recruiting nowThis pilot trial is testing a type of radiation called hypofractionated stereotactic radiosurgery for people who have had surgery for a grade II or recurrent grade I meningioma. The treatment delivers higher doses of radiation in fewer sessions, which may kill leftover tumor cell…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for advanced cancer patients: SKB103 trial now recruiting
Disease control Recruiting nowThis study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cancer drug AMT-676 enters first human tests
Disease control Recruiting nowThis early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…
Phase: EARLY_PHASE1 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a transplant drug shrink dangerous blood vessel tangles?
Disease control Recruiting nowThis study tests whether sirolimus, a drug used to prevent organ rejection, can shrink severe arteriovenous malformations (AVMs) and ease symptoms. About 50 people aged 2 and older with advanced AVMs will take the drug for a year. The goal is to see if the drug reduces AVM size b…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…
Phase: PHASE1 • Sponsor: Jun Zhou • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug PEEL-224 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tu…
Phase: PHASE1 • Sponsor: Peel Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immune cell 'Packages' injected into tumors: a new hope for advanced cancer?
Disease control Recruiting nowThis early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. Th…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for advanced cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for young cancer patients: drug may fix Chemo-Related low platelets
Disease control Recruiting nowThis study tests a drug called romiplostim N01 in children, adolescents, and young adults (ages 6-24) with cancer who develop low platelet counts from chemotherapy. The drug is given as a weekly shot to help the body produce more platelets. The goal is to see if it can safely and…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New Needle-Free treatment could replace surgery for adrenal tumors
Disease control Recruiting nowThis study compares a new, less invasive procedure called EUS-RFA to standard surgery for treating left-sided adrenal tumors that cause high blood pressure and other hormone-related issues. About 60 participants will receive the new procedure, which uses a thin tube inserted thro…
Phase: NA • Sponsor: Haukeland University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for rare vascular malformations: targeted drugs enter trial
Disease control Recruiting nowThis phase 2 trial is testing two targeted drugs—alpelisib and mirdametinib—in 50 people with slow-flow or fast-flow vascular malformations that haven't responded to standard treatments. The goal is to see if these drugs can improve each person's most bothersome symptom over 48 w…
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Bacteria engineered to starve tumors enters human trials
Disease control Recruiting nowThis early-phase trial is testing a modified salmonella bacteria, called SGN1, in 70 people with advanced solid tumors that have not responded to standard treatments. The bacteria are designed to grow inside tumors and release an enzyme that breaks down methionine, an amino acid …
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Cancer-fighting virus plus immunotherapy shows promise in advanced tumors
Disease control Recruiting nowThis study tests a modified herpesvirus (T3011) combined with standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink tumors. About 68 parti…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug MDX2001 tested in 285 patients with advanced cancers
Disease control Recruiting nowThis study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…
Phase: PHASE1, PHASE2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for stubborn warts: extended treatment shows promise
Disease control Recruiting nowThis study follows people who already took part in earlier YCANTH wart studies. It tests whether up to 4 more treatments, applied every 21 days, can safely clear common warts. About 600 adults and children will be monitored for a year. The goal is to see if the medicine continues…
Phase: PHASE3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Bacteria battle cancer: modified salmonella starves tumors in new trial
Disease control Recruiting nowThis study tests a modified salmonella bacteria (SGN1) injected directly into tumors. The bacteria are designed to grow inside tumors and cut off their food supply (an amino acid called methionine), causing the tumors to shrink. The trial involves about 70 adults with advanced so…
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Engineered immune cells take on Cancer-Related fluid swelling
Disease control Recruiting nowThis early-phase trial is testing a new treatment called NK521 for people with advanced solid tumors that have spread and caused fluid buildup in the belly (malignant ascites). The treatment uses a person's own natural killer (NK) cells that have been gene-edited to better attack…
Phase: EARLY_PHASE1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Smart drug delivers chemo directly to cancer cells in new trial
Disease control Recruiting nowThis study tests a new drug called CKD-703 in people with advanced solid tumors or non-small cell lung cancer that has a specific protein (c-Met). The drug is designed to attach to cancer cells and release chemotherapy directly inside them, aiming to kill the cancer while reducin…
Phase: PHASE1, PHASE2 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Bacteria injected into tumors: a new hope for cancer patients?
Disease control Recruiting nowThis early-phase trial is testing whether a specially designed bacteria, CMTS1215, can safely shrink solid tumors. About 20 adults with advanced solid tumors who have no other treatment options will receive the bacteria directly into their tumor or through a vein. The main goals …
Phase: PHASE1, PHASE2 • Sponsor: The Second Hospital of Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New antibody drug AM-928 enters early human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called AM-928, given as an IV infusion, in about 38 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for ear…
Phase: PHASE1 • Sponsor: AcadeMab Biomedical Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New pill shows promise against tough cancers and brain tumors
Disease control Recruiting nowThis study tests an experimental oral drug called NBM-BMX in people with advanced solid tumors or newly diagnosed glioblastoma (a type of brain cancer). The drug is given alone for solid tumors or combined with standard treatments (radiation and chemotherapy) for brain cancer. Th…
Phase: PHASE1, PHASE2 • Sponsor: Novelwise Pharmaceutical Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Cream vs. freeze: new study tests easier treatment for stubborn foot warts
Disease control Recruiting nowThis study compares two treatments for recurrent plantar warts: a topical adapalene gel (a type of retinoid cream) and cryotherapy (freezing with liquid nitrogen). Researchers will enroll 98 adults aged 18-60 with recurring warts on the soles of their feet. The goal is to see whi…
Phase: PHASE4 • Sponsor: Khyber Teaching Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Immune cell therapy GT201 targets advanced tumors in early trial
Disease control Recruiting nowThis study tests an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced solid tumors. About 18 adults will receive the treatment to see if it is safe and can shrink tumors. The goal is to control the disease, no…
Phase: PHASE1, PHASE2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for advanced cancer? early trial of HWS116 begins
Disease control Recruiting nowThis early-stage study tests a new drug called HWS116 in about 56 adults with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check the drug's safety and see if it can shrink tumors.…
Phase: PHASE1 • Sponsor: Wuhan Humanwell Innovative Drug Research and Development Center Limited Company • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New program aims to cut risky drug mix-ups for kids on multiple medications
Disease control Recruiting nowThis study tests a program called Pediatric Medication Therapy Management (pMTM) for children with complex medical conditions who take five or more medications. The program involves a thorough review of all medicines, optimizing the regimen, and creating a clear medication plan. …
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New pill targets RET-Driven cancers in early trial
Disease control Recruiting nowThis study tests a new oral drug called HEC169096 in people with advanced solid tumors, including thyroid cancer and non-small cell lung cancer, that have a specific RET gene change. The trial has two phases: the first finds the safest dose, and the second checks how well the dru…
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New gel could ease painful skin growths
Disease control Recruiting nowThis phase 2 trial tests a gel called PTX-022 (sirolimus) on people aged 6 and older with angiokeratomas, which are small, raised skin spots. The study will check if the gel is safe and helps improve the appearance of these spots. Fifteen participants will apply the gel and be mo…
Phase: PHASE2 • Sponsor: Palvella Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New radiation 'Lattice' method paired with immunotherapy shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for advanced cancer: experimental drug IMC-002 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…
Phase: PHASE1 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare genetic cancers? drug targets POLE/POLD1 mutations
Disease control Recruiting nowThis study tests a drug called toripalimab, which helps the immune system fight cancer, in people with advanced solid tumors that have specific genetic changes (POLE or POLD1 mutations) and have not responded to standard treatments. The trial aims to see if the drug can shrink tu…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a simple cream replace freezing for Kids' warts?
Disease control Recruiting nowThis study tests a cream called tirbanibulin on hand warts in children aged 8 to 18. Warts are common but current treatments like freezing can be painful and scary for kids. The cream is applied at home and may clear warts with less discomfort. Only 10 children will take part to …
Phase: PHASE4 • Sponsor: The Skin Center Dermatology Group • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cancer Patients' egg freezing: which trigger works best?
Disease control Recruiting nowThis study looks at two ways to trigger ovulation in women with cancer who are freezing their eggs before chemotherapy. One method uses a GnRH agonist alone, the other combines it with hCG (dual trigger). The goal is to see which approach retrieves more eggs while reducing the ri…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug combo enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug called GS-2121, taken as a tablet, alone or with an intravenous drug called zimberelimab, in 154 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, …
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug HS-20110 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. Participants receive HS-20110 by IV infusion in 21-day c…
Phase: PHASE1 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for advanced cancer: experimental drug HDM2024 enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called HDM2024 in 63 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check if the drug is safe and to see if it can shrink tumors. Participants receive the drug once every three weeks,…
Phase: PHASE1 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New cancer drug DXP-106 enters early human testing
Disease control Recruiting nowThis early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…
Phase: PHASE1 • Sponsor: Singlomics Biopharmaceuticals Zhuhai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for advanced cancers: experimental drug XNW28012 enters human trials
Disease control Recruiting nowThis study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Heat and hydrogen peroxide patch takes on stubborn warts
Disease control Recruiting nowThis study tests whether adding a microneedle patch soaked in hydrogen peroxide to local heat therapy can clear viral warts better than heat alone. About 210 people aged 6–65 with common or plantar warts will be split into three groups: heat only, heat plus a plain patch, or heat…
Phase: NA • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug ATG-022 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…
Phase: PHASE1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis phase IIa trial is testing two experimental drugs, HX009 and IN10018, given together with or without standard chemotherapy, in 124 adults with advanced solid tumors, specifically biliary tract cancer and melanoma. The study aims to find the best dose and see if the combinati…
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New CAR-T therapy aims to outsmart Hard-to-Treat solid cancers
Disease control Recruiting nowThis early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New study tests best method to cut blood loss in fibroid surgery
Disease control Recruiting nowThis study compares two surgical techniques to reduce blood loss during open fibroid removal. Forty women with symptomatic uterine fibroids will be randomly assigned to either bilateral uterine artery ligation or a pericervical mechanical tourniquet. The goal is to see which meth…
Phase: NA • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Bacteria injected into tumors: a new weapon against cancer?
Disease control Recruiting nowThis early-stage trial tests a genetically modified version of the Yersinia enterocolitica bacterium, given alone or with the immunotherapy pembrolizumab, in 100 adults with advanced solid tumors that have no standard treatment options. The goal is to find a safe dose and see if …
Phase: PHASE1, PHASE2 • Sponsor: T3 Pharmaceuticals AG • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Smart pump trial aims to ease diabetes management for kids
Disease control Recruiting nowThis study follows 120 Israeli children and teens with type 1 diabetes who use the Medtronic 780G system, a closed-loop insulin pump that automatically adjusts insulin. Researchers will track blood sugar control, sleep, diet, and emotional well-being over two years. The goal is t…
Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill HQP1351 enters human testing for stubborn cancers
Disease control Recruiting nowThis early-stage trial is testing an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors. The main goal is to find a safe dose and see how the body handles the drug. Participants take the pill every other day for…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Off-the-Shelf immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infu…
Phase: PHASE1 • Sponsor: Shanghai NK Cell Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New cancer drug DB-1310 enters first human trials
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called DB-1310 in 1000 adults with advanced solid tumors that have worsened after standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. It is a first-in-human study, so the main…
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental drug combo takes on advanced cancers
Disease control Recruiting nowThis study tests two experimental drugs, QLP2117 and QL2107, given together to people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 149 participants will be enrolled i…
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New pill shows early promise against tough cancers
Disease control Recruiting nowThis early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Resear…
Phase: PHASE1 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug SYS6043 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early si…
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New pill shows promise against resistant cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new oral drug, TSL2109, in people with advanced solid tumors, especially prostate and breast cancers that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors o…
Phase: PHASE1 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …
Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Cutting protein may supercharge cancer fight
Disease control Recruiting nowThis study tests whether eating low-protein meals (10% protein instead of the usual 20%) can boost the immune system's response to immunotherapy in cancer patients. Researchers will enroll 30 adults with solid tumors that have spread. The main goal is to see if patients can stick…
Phase: NA • Sponsor: State University of New York at Buffalo • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for advanced tumors? HRS-8364 enters human trials
Disease control Recruiting nowThis study tests a new drug called HRS-8364 in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose and check how well the drug shrinks tumors. About 282 participants will take part across multiple ce…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for advanced cancer? early trial of WJB001 begins
Disease control Recruiting nowThis early-phase study tests an experimental drug called WJB001 in people with advanced solid tumors who have no standard treatment options left. The trial has three parts: first, finding a safe dose; second, checking how well that dose works; and third, testing it in specific tu…
Phase: PHASE1, PHASE2 • Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New device aims to seal brain blood vessel leaks in kids
Disease control Recruiting nowThis study looks at how well the PHIL Embolic System works to treat a rare brain condition in children called dural arteriovenous fistulas (DAVFs), where blood vessels connect abnormally. About 15 children under 22 will receive the treatment, which uses a special material to bloc…
Phase: NA • Sponsor: Alejandro Berenstein • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…
Phase: PHASE1, PHASE2 • Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New daily pill hopes to control advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…
Phase: PHASE1, PHASE2 • Sponsor: 858 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a plant extract reduce thyroid nodules? new study seeks answers
Disease control Recruiting nowThis study tests whether Prunella oral liquid, a herbal remedy, can safely shrink benign (non-cancerous) thyroid nodules. About 234 adults with solid nodules between 1 and 3 cm will take the liquid or a placebo for 9 months. Researchers will measure changes in nodule size and che…
Phase: PHASE4 • Sponsor: Xintian Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New immunotherapy combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing whether combining two drugs—Envafolimab (an immunotherapy injection) and Lenvatinib (a daily pill)—can shrink tumors in people with advanced solid cancers like lung, kidney, and liver cancer. About 170 adults whose cancer has worsened after standard treatmen…
Phase: PHASE1, PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New immunotherapy shot targets tumors with many mutations
Disease control Recruiting nowThis phase 2 trial is testing Envafolimab, an immunotherapy drug given as a shot, in 126 adults with advanced solid tumors that have not responded to standard treatments. The study aims to see if patients with a high number of tumor mutations respond better than those with fewer …
Phase: PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis phase 2 trial is testing an immunotherapy drug called KN035, given as a shot under the skin, for people with advanced solid tumors that have specific genetic features (dMMR or MSI-H). The study includes 200 participants with colorectal cancer or other solid tumors who have a…
Phase: PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shield for chemo patients: can trilaciclib prevent dangerous side effects?
Disease control Recruiting nowThis study tests a drug called trilaciclib to protect bone marrow in people with solid tumors receiving chemotherapy. The goal is to reduce severe drops in blood cells, which can be dangerous and delay treatment. Researchers will build a model to predict who benefits most from th…
Phase: PHASE1 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called Enhanced ALPP CAR-T cells for people with advanced solid tumors that have not responded to standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to recognize and attack cancer cells that hav…
Phase: EARLY_PHASE1 • Sponsor: TCRCure Biopharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill for tough tumors enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental pill called ABSK021 in people with advanced solid tumors (including a rare joint tumor called TGCT) who have run out of standard options. The main goal is to check safety and find the best dose, while also seeing if the drug can shrink…
Phase: PHASE1 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests whether two experimental drugs, AK119 and AK112, can safely shrink or control advanced solid tumors that have stopped responding to standard treatments. About 87 adults with various solid tumors will receive the drug combination. The main goals are to check safet…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental mitochondrial vaccine takes on advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an engineered mitochondrial vaccine in 12 people with advanced solid tumors who cannot have standard treatments. The vaccine is given as a series of shots to see if it is safe and can help control the cancer. The study focuses on safety first, wi…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Fiber fuel: could a High-Fiber diet boost cancer treatment?
Disease control Recruiting nowThis study looks at whether eating a high-fiber diet (over 21 grams per day) can change gut bacteria and improve the immune system's ability to fight solid tumors like colorectal cancer. About 25 adults with solid tumors will follow this diet to see if it is safe and helps with t…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses an…
Phase: PHASE1 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Immune cell double punch takes on Hard-to-Treat tumors
Disease control Recruiting nowThis early-stage study is testing a new two-part immune therapy for people with advanced solid cancers like stomach, colon, or pancreatic cancer. The treatment combines special dendritic cells that guide the immune system to the tumor with CAR-T cells that directly attack cancer …
Phase: EARLY_PHASE1 • Sponsor: Hainan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Common diabetes drug may shield kidneys from chemo damage
Disease control Recruiting nowThis study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for a few days around their chemo session. Researche…
Phase: PHASE2 • Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for Hard-to-Treat cancers: targeted drug enters human trials
Disease control Recruiting nowThis study tests a new drug called ABSK141 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer will…
Phase: PHASE1, PHASE2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New targeted pill shows promise for Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis phase 2 trial is testing a daily pill called JAB-21822 (Glecirasib) in 88 people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. Participants must have already tried standard treatments without success. The main goal is to see i…
Phase: PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill could ease heavy periods from fibroids
Disease control Recruiting nowThis study tests a new drug called CMS-D002 for women with uterine fibroids who have heavy menstrual bleeding. About 120 women aged 18-50 will take either the drug or a placebo daily for 12 weeks. The goal is to see if the drug can reduce bleeding to normal levels and shrink fibr…
Phase: PHASE2 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental drug cocktail takes on Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing two experimental drugs, 7MW3711 and JS207, given together (with or without chemotherapy) in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then checking how wel…
Phase: PHASE1, PHASE2 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New injection targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…
Phase: PHASE1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New smart drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called JK06, designed to seek out and attack cancer cells while sparing healthy ones. It is for adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the safest dose and see if the drug can shrin…
Phase: PHASE1, PHASE2 • Sponsor: Salubris Biotherapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug duo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Weekly pill could tame painful birthmarks with fewer side effects
Disease control Recruiting nowThis study tests whether taking the drug sirolimus just once a week can safely treat venous and lymphatic malformations—abnormal clusters of blood vessels or lymph vessels that can cause pain and swelling. Current daily dosing works but often causes side effects like low white bl…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug Hemay181 tested in patients with advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called Hemay181 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goal is to see if the drug can shrink tumors and to check for side effects. Participants will recei…
Phase: PHASE1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New antibody drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called CDR404 in up to 42 adults with advanced solid tumors that have a specific marker (MAGE-A4) and tissue type (HLA-A*02:01). The drug is designed to help the body's immune T-cells find and attack cancer cells. The main goals are to chec…
Phase: PHASE1 • Sponsor: CDR-Life AG • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New iron injection shows promise in shrinking tumors
Disease control Recruiting nowThis study tests a new drug called CNSI-Fe(II), which is injected directly into tumors. It uses iron to trigger a type of cell death called ferroptosis, aiming to control advanced solid tumors like lung, pancreas, and colorectal cancers. The trial involves 54 adults whose current…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Enray Pharmaceutical Sciences Company • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy aims to extend life in advanced melanoma
Disease control Recruiting nowThis study tests a new drug, tebentafusp, alone or with pembrolizumab, in people with a specific genetic type (HLA-A*02:01) of advanced melanoma that has been treated before. The main goal is to see if these treatments help people live longer compared to other available options. …
Phase: PHASE3 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New targeted drug SYS6043 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The trial will first find the safest dose, then expand to…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Engineered donor cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could early radiation prevent spine fractures in cancer patients?
Disease control Recruiting nowThis study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …
Phase: PHASE1, PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New shorter radiation therapy could tame brain tumors
Disease control Recruiting nowThis study tests a shorter course of high-dose proton radiation for people with non-cancerous brain tumors like meningiomas and schwannomas. The goal is to see if fewer treatments can still control tumor growth while reducing side effects and being more convenient. About 70 adult…
Phase: NA • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Immune cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Glow-in-the-Dark dye could make Children's tumor surgery safer and more effective
Disease control Recruiting nowThis study tests whether a special dye (indocyanine green) that glows under a special camera can help surgeons better see and remove cystic lymphatic malformations in children. About 110 children will be randomly assigned to either standard surgery or surgery guided by this dye. …
Phase: NA • Sponsor: Nanjing Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New antibody combo shows promise in early cancer trial
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…
Phase: PHASE1, PHASE2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could a simple supplement shrink fibroids and prevent surgery?
Disease control Recruiting nowThis study tests whether a daily supplement containing vitamin D, EGCG (from green tea), D-chiro-inositol, and vitamin B6 can shrink uterine fibroids in women who are eligible for surgery. Sixty women will take either the supplement or a placebo for three months. The main goal is…
Phase: NA • Sponsor: Lo.Li.Pharma s.r.l • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New cancer drug TORL-1-23 enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find…
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New study seeks safer dosing of cancer drug for patients with liver issues
Disease control Recruiting nowThis early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receiv…
Phase: PHASE1 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New cancer drug AGX101 enters human trials for advanced tumors
Disease control Recruiting nowThis early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…
Phase: PHASE1 • Sponsor: Angiex, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
BioNTech launches first human test of BNT317 against advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug ORB-021 enters early human testing for advanced cancers
Disease control Recruiting nowThis early-phase trial is testing whether a new drug called ORB-021 is safe and tolerable for people with advanced solid tumors who have no standard treatment options left. About 36 adults will receive the drug through an IV to find the best dose for future studies. The main goal…
Phase: PHASE1 • Sponsor: Orionis Biosciences Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New targeted drug BAT8008 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called BAT8008 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target a protein called Trop2 found on many cancer cells. The main goals are to check safety, find the best dos…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can MRI outsmart blood tests for prostate cancer?
Diagnosis Recruiting nowThis study enrolls 950 men with suspected but undiagnosed prostate cancer who are scheduled for a biopsy. Researchers will compare the accuracy of prostate MRI against a panel of blood and urine biomarkers (PCA3, PSA, TMPRSS2:ERG) in detecting clinically significant prostate canc…
Sponsor: University of Michigan • Aim: Diagnosis
Last updated Aug 18, 2026 02:00 UTC
-
Can a new PET tracer reveal a key cancer target?
Diagnosis Recruiting nowThis trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
New scan could spare thousands from unnecessary kidney surgery
Diagnosis Recruiting nowThis study is testing whether a combined PET and MRI scan (PET/MR) can better tell apart aggressive kidney cancers from slow-growing or harmless tumors. About 97 adults with a suspicious kidney mass will receive the scan during their regular MRI appointment. Researchers hope this…
Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowThis study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
New rapid test could save lives of febrile children in africa
Diagnosis Recruiting nowThis study tests whether a rapid triage test (suPAR) can help doctors make better decisions about admitting or discharging children with fever. Over 5,000 children aged 2 months to 5 years in sub-Saharan Africa will be randomly assigned to standard care or standard care plus the …
Phase: NA • Sponsor: Barcelona Institute for Global Health • Aim: Diagnosis
Last updated Jul 30, 2026 00:00 UTC
-
Can a tracer that hunts unstable iron light up hidden tumors?
Diagnosis Recruiting nowThis phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…
Phase: PHASE1 • Sponsor: Rahul Aggarwal • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New PET tracer targets cancer cells for sharper tumor imaging
Diagnosis Recruiting nowThis study tests a new imaging agent called F18 FBPA, which is designed to light up cancer cells during a PET/CT scan. The agent targets a protein often found on solid tumors, potentially making tumors easier to see. Researchers want to find the best dose and timing for the scan,…
Phase: PHASE1, PHASE2 • Sponsor: Heron Neutron Medical Corp. • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
Fewer needles, same safety? new study tests smarter prostate cancer detection.
Diagnosis Recruiting nowThis study tests whether men with very high PSA and suspicious MRI can safely skip the painful 12-needle systematic biopsy and rely only on targeted samples. Over 1,200 men will get both biopsies, but each sample is analyzed separately to see how often the extra needles find dang…
Phase: NA • Sponsor: Shanghai East Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
Phone AI could spot eye disease in remote areas
Diagnosis Recruiting nowThis study tests a smartphone app that uses artificial intelligence to detect 16 different eye diseases from photos taken with the phone. The AI works entirely on the device, so no internet is needed. Researchers will compare its accuracy to eye doctors and see if non-medical use…
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New ultrasound technique could spot breast cancer without a needle
Diagnosis Recruiting nowThis study is testing a new, non-invasive ultrasound method to see if it can tell the difference between benign and malignant breast tumors. Researchers will also check if it can measure how well breast cancer responds to chemotherapy. Up to 250 women with breast lumps or breast …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New MRI scan could reveal Cancer's true aggressiveness
Diagnosis Recruiting nowThis study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is …
Phase: PHASE1, PHASE2 • Sponsor: Robert Bok, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Simple blood test could spot multiple cancers early
Diagnosis Recruiting nowThis study is testing a new blood test that looks for DNA from cancer cells. The goal is to see if an artificial intelligence program can accurately detect many different types of cancer at an early stage. The study will include 6,000 adults, some with cancer and some healthy vol…
Sponsor: Chang Gon Kim • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
No-Radiation breast scanner could change cancer detection
Diagnosis Recruiting nowThis study is testing a new device called MammoWave that uses low-power microwaves instead of X-rays to find breast lesions. About 600 women will lie face-down while the device scans their breasts for about 10 minutes. The goal is to see if this safe, radiation-free method can ac…
Phase: NA • Sponsor: Umbria Bioengineering Technologies • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
New blood test could spot multiple cancers before symptoms appear
Diagnosis Recruiting nowThis study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test wo…
Sponsor: ClearNote Health • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New PET scan agent aims to better detect rare tumors
Diagnosis Recruiting nowThis study tests a new radioactive imaging agent called 68Ga-HA-DOTATATE to see if it can safely and accurately detect neuroendocrine tumors using PET/CT scans. About 600 people with known or suspected tumors will receive the agent and be followed for one year. The goal is to imp…
Phase: PHASE2 • Sponsor: University of Alberta • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
New PET tracer may reveal hidden cancer targets
Diagnosis Recruiting nowThis early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where i…
Phase: EARLY_PHASE1 • Sponsor: National Cancer Institute, Naples • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Light may replace needle for breast cancer diagnosis
Diagnosis Recruiting nowThis study is testing whether special light-based scans (photoacoustic imaging and diffuse reflectance spectroscopy) can tell the difference between healthy, benign, and malignant breast tissue. Researchers will scan 90 women with known breast lumps and compare the scan results t…
Phase: NA • Sponsor: Region Skane • Aim: Diagnosis
Last updated Jun 27, 2026 12:25 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden cancer
Diagnosis Recruiting nowThis early-stage trial is testing an injectable dye called NC527-X that may make tumors glow during surgery, helping surgeons see exactly where the cancer is. The study will enroll 400 adults with solid tumors who are already scheduled for surgery. Participants receive one of fou…
Phase: PHASE1 • Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:10 UTC
-
New PET scan probe could spot hidden tumors
Diagnosis Recruiting nowThis study tests a new imaging probe called 89Zr-s-C1 that attaches to a protein (MUC18) found on some solid tumors. The goal is to see if this PET/CT scan can find tumors that standard scans miss. About 20 adults with newly diagnosed or recurring solid tumors (like melanoma or s…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC
-
New PET scan tracer could reveal hidden cancer markers
Diagnosis Recruiting nowThis study tests a new radioactive tracer called [68Ga]Ga-THP-PDL1-3 for PET/CT scans in 50 adults with solid tumors. The goal is to see if it can safely and accurately show PD-L1 levels in tumors, which may help doctors personalize cancer treatment. Participants will receive bot…
Phase: NA • Sponsor: Hua Zhu • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New 3D ultrasound aims to improve breast cancer diagnosis without radiation
Diagnosis Recruiting nowThis study is testing a new 3D automated ultrasound system called ATUSA to see how well it can image suspicious breast lesions. Up to 800 women with suspicious findings on standard imaging will get an ATUSA scan before their biopsy. The goal is to collect images and compare them …
Sponsor: iSono Health, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
New PET tracer could light up hidden cancers
Diagnosis Recruiting nowThis early-stage study is testing a new radioactive dye called RT01-89Zr that attaches to a protein found on many solid tumor cells. The goal is to see if it can safely and clearly show tumors on PET/CT scans. About 10 adults with advanced solid tumors will receive the dye and be…
Phase: EARLY_PHASE1 • Sponsor: Nanolattix Biotechnology Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
Massive study aims to catch kidney disease early in 13,000 children
Diagnosis Recruiting nowThis study will screen 13,000 children in China using urine tests and ultrasound to find kidney disease early. The goal is to see how common kidney problems are in kids and to build a system to predict who is at risk. Children with abnormal results will be referred for further ca…
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
New scanner uses light and sound to spot breast tumors without needles
Diagnosis Recruiting nowThis study is testing a new device called the Photo-Acoustic Imager 3+ (PAM3+) that uses light and sound waves to create images of breast tissue. The goal is to see how well it can find both benign and malignant breast lesions in women referred to a breast clinic. About 180 women…
Phase: PHASE2 • Sponsor: Franciscus Gasthuis & Vlietland (Hospital) • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
Blood test may spot pancreatic cancer early, study hopes
Diagnosis Recruiting nowThis study aims to find blood-based biomarkers that can distinguish malignant pancreatic lesions from benign ones. Researchers will analyze blood samples from 100 adults with benign pancreatic conditions and compare them to existing data from patients with pancreatic cancer. The …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New ultrasound trick could spare women unnecessary breast biopsies
Diagnosis Recruiting nowThis study is testing a new way to use Doppler ultrasound to better tell the difference between benign (non-cancerous) and malignant (cancerous) breast lumps. Researchers will measure blood flow resistance in the lump and compare it to healthy breast tissue. If the method works, …
Sponsor: Ahmet Yesildag • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New scan could reveal hidden diseases
Diagnosis Recruiting nowThis study tests a new radioactive dye called 68Ga-NI-FAPI for PET/CT scans. It aims to better detect diseases like tumors, heart problems, and lung scarring by targeting a protein linked to tissue damage. About 30 people, including healthy volunteers and patients, will take part…
Phase: PHASE1, PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Targeted PET scan spots cancer protein, guiding treatment
Diagnosis Recruiting nowThis study tests a new PET scan that uses a special tracer to find a protein called CLDN18.2 on solid tumors. The goal is to see if this scan can help identify which patients might benefit from treatments that target this protein. About 15 adults with solid tumors will receive th…
Phase: NA • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Ultrasound may spot endometriosis without surgery
Diagnosis Recruiting nowThis study tests whether a specific ultrasound measurement can reliably detect superficial endometriosis on the uterosacral ligaments. Researchers will compare ultrasound findings with laparoscopic surgery results in 64 women undergoing gynecological surgery. If a clear cutoff th…
Sponsor: Casa di Cura Dott. Pederzoli • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New ultrasound trick could replace costly scans for common liver tumors
Diagnosis Recruiting nowThis study tests a new computer-based ultrasound technique called Fluctuational Imaging (FLI) to diagnose hepatic hemangiomas, the most common benign liver tumors. Researchers will enroll 400 adults with liver lesions to see if FLI can reliably tell hemangiomas apart from other g…
Sponsor: Yonsei University • Aim: Diagnosis
Last updated Jun 27, 2026 09:06 UTC
-
Headband device could spot hidden shunts without needles
Diagnosis Recruiting nowThis study tests a head-worn ultrasound device called SONAS that listens for bubble signals in the brain during a standard heart ultrasound. It aims to see if the device can accurately detect right-to-left shunts—abnormal connections between blood vessels—in adults with hereditar…
Phase: NA • Sponsor: St. Antonius Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:06 UTC
-
New shot could stop deadly clots in cancer patients
Prevention Recruiting nowThis phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC
-
Green tea and vitamin D3 may stop fibroids returning after surgery
Prevention Recruiting nowThis study tests whether taking green tea extract (EGCG) and vitamin D3 daily can prevent uterine fibroids from growing back after surgical removal. About 240 women who have had fibroid surgery will receive either the supplements or a placebo. The goal is to see if this simple co…
Phase: PHASE2 • Sponsor: Sheikh Shakhbout Medical City • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Vitamin B12 trial aims to stop Chemo's painful side effect
Prevention Recruiting nowThis study tests whether taking mecobalamin (a form of vitamin B12) can prevent or reduce nerve damage caused by taxane chemotherapy. About 326 adults with various solid tumors will take mecobalamin tablets or receive no preventive treatment during their chemo. The goal is to see…
Phase: PHASE3 • Sponsor: Qinghai Red Cross Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:26 UTC
-
A good Night's sleep: could a simple program ease Cancer's toll on rest?
Symptom relief Recruiting nowThis study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can heat melt away lipomas without a scalpel?
Symptom relief Recruiting nowThis trial tests whether radiofrequency ablation (RFA) can safely and effectively treat superficial lipomas—benign fatty lumps under the skin—without leaving a scar. Instead of cutting out the lipoma, a thin needle delivers heat to melt it, guided by ultrasound. The study will me…
Phase: NA • Sponsor: Columbia University • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Magic mushroom compound tested for cancer pain that opioids Can't touch
Symptom relief Recruiting nowThis study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approa…
Phase: PHASE2 • Sponsor: Yvan Beaussant, MD, MSci • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Mushroom extract put to the test for advanced cancer Well-Being
Symptom relief Recruiting nowThis trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
A simple diet and muscle relaxant may sharpen views in scarless hysterectomy
Symptom relief Recruiting nowThis trial tests whether a three-day low-residue diet and deeper muscle relaxation, alone or together, can improve the surgical view during vNOTES hysterectomy (a scarless procedure through the vagina). The study involves 160 women having hysterectomy for non-cancer conditions. R…
Phase: NA • Sponsor: Fatih Sultan Mehmet Training and Research Hospital • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Could a homeopathic remedy ease cancer treatment fatigue?
Symptom relief Recruiting nowThis study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…
Phase: EARLY_PHASE1 • Sponsor: Beaura for Para Pharmaceutical Products Trading LLC • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could a Steroid-Sparing cocktail tame chemo nausea?
Symptom relief Recruiting nowThis phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study en…
Phase: PHASE2 • Sponsor: Mahidol University • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Could a nurse-led online therapy beat severe fatigue in advanced cancer?
Symptom relief Recruiting nowThis trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Simple injection may ease pain after hysterectomy surgery
Symptom relief Recruiting nowThis study tests whether injecting the local anesthetic bupivacaine into the small surgical cuts and the vaginal cuff at the end of a laparoscopic hysterectomy can lower postoperative pain. 120 women having the surgery for non-cancer reasons will be randomly assigned to receive t…
Phase: NA • Sponsor: Serkan Kumbasar • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Can a psoriasis drug tame Immunotherapy's harsh side effects?
Symptom relief Recruiting nowThis pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…
Phase: PHASE1 • Sponsor: Brian Henick, MD • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Old-School game Kho-Kho put to the test for boosting Kids' agility
Symptom relief Recruiting nowThis study tests whether playing Kho-Kho, a traditional Indian tag game, can improve agility and reaction time in school children aged 8 to 12. Over 6 weeks, 48 kids will either play Kho-Kho or do free play three times a week. Researchers will measure changes in agility and react…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Card game aims to ease tough End-of-Life talks for cancer patients
Symptom relief Recruiting nowThis study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…
Phase: NA • Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Heat and hydrogen peroxide: a new hope for stubborn warts?
Symptom relief Recruiting nowThis study tests whether combining heat therapy (hyperthermia) with a common antiseptic (3% hydrogen peroxide) can clear stubborn viral warts that haven't responded to other treatments. About 80 adults with warts lasting two years or more will receive either the combination treat…
Phase: NA • Sponsor: First Hospital of China Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New lattice radiation aims to shrink bulky tumors and ease pain
Symptom relief Recruiting nowThis study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better than standard radiation and help people feel better. About 37 adults with advanced solid tumors will receive this tre…
Phase: PHASE2 • Sponsor: University of Cincinnati • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Gaming away chemo sickness: iPad game tested in seniors
Symptom relief Recruiting nowThis study tests whether playing a serious game on an iPad can help older adults (60+) better manage nausea and vomiting caused by chemotherapy. About 610 participants will be randomly assigned to play the game or receive usual care. Researchers will track symptom severity, quali…
Phase: NA • Sponsor: University of Central Florida • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Cool cap could keep Kids' hair safe during chemo
Symptom relief Recruiting nowThis study tests whether a special cooling cap can prevent hair loss in children receiving chemotherapy for non-cancerous conditions or solid tumors. The cap is worn before, during, and after chemo to keep the scalp cool. Researchers want to see if it is safe and tolerable for 40…
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Five-minute video may ease tough choices for fibroid patients
Symptom relief Recruiting nowThis study tests whether a 5-minute educational video about uterine fibroids and their treatments can help patients feel less conflicted when deciding on a treatment plan. About 154 women with fibroids will be randomly assigned to watch the video before their appointment or recei…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New pill could ease pain after wisdom tooth surgery
Symptom relief Recruiting nowThis Phase 2 trial tests a single oral dose of LY4515100 against a placebo in 212 people with moderate-to-severe pain after having their wisdom teeth removed. The goal is to see if the drug safely reduces pain intensity and how quickly it works. Participants stay in a research un…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Which cancer care model boosts quality of life? large trial seeks answers
Symptom relief Recruiting nowThis study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Could a simple salt water injection melt away fatty lumps?
Symptom relief Recruiting nowThis study is testing whether injecting cooled or warmed salt water (saline) directly into lipomas—harmless fatty lumps under the skin—can shrink them. About 20 adults with at least one lipoma will receive up to four treatments, each four weeks apart. The goal is to see if this s…
Phase: PHASE1, PHASE2 • Sponsor: West Virginia University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New day hospital aims to ease transition for young cancer survivors
Symptom relief Recruiting nowThis study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…
Phase: NA • Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Hypnosis may calm cancer patients during radiation
Symptom relief Recruiting nowThis study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …
Phase: PHASE2 • Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Jun 27, 2026 12:10 UTC
-
Can a lidocaine spray stop Post-Surgery shoulder pain?
Symptom relief Recruiting nowThis study tests whether spraying a low-dose lidocaine solution under the diaphragm during single-incision laparoscopic surgery can reduce shoulder pain afterward. About 100 women having surgery for benign gynecological conditions like ovarian cysts or uterine fibroids will take …
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Sound waves vs. scalpel: new trial tests ultrasound as fibroid fix
Symptom relief Recruiting nowThis study compares High-Intensity Focused Ultrasound (HIFU), a non-invasive procedure using sound waves to destroy fibroids, to myomectomy, a surgical removal. About 112 women aged 18-50 with symptomatic fibroids will be randomly assigned to one treatment. Researchers will track…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New bipolar knife could make esophageal surgery safer
Symptom relief Recruiting nowThis study tests a new device called the Speedboat™ Ultraslim, a bipolar radiofrequency knife, for removing precancerous growths in the esophagus. Researchers want to see if it works well and is safe compared to standard tools. The trial will involve 50 adults at two medical cent…
Sponsor: Baylor College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Robot buddies let kids with cancer attend class from hospital bed
Symptom relief Recruiting nowThis study tests whether telepresence robots can help children aged 5-17 with cancer attend school remotely when they can't be there in person. The robots let kids see, hear, and talk in class from their hospital or home. Researchers will track school attendance, social well-bein…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Nurse chats could ease cancer kids' suffering
Symptom relief Recruiting nowThis study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Acupuncture meets medicine: new combo targets Post-Surgery nausea
Symptom relief Recruiting nowThis study tests whether adding a gentle electrical acupoint stimulation (TEAS) to a standard three-drug anti-nausea regimen can further reduce vomiting after laparoscopic surgery. Researchers will compare active TEAS to a sham (fake) version in 780 women at high risk for postope…
Phase: NA • Sponsor: Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Custom masks could help kids breathe easier at night
Symptom relief Recruiting nowThis study tests whether custom-made 3D-printed masks fit children better than standard commercial masks for non-invasive ventilation (NIV). Fifteen children aged 8-12 who already use NIV but have poor adherence will try a custom mask made from a 3D facial scan. Researchers will …
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Zapping thyroid nodules: a Needle-Free alternative to surgery?
Symptom relief Recruiting nowThis study tracks 50 people who choose radiofrequency ablation (RFA) for benign thyroid nodules or low-risk papillary thyroid cancer instead of surgery. Researchers will monitor long-term outcomes and quality of life using questionnaires. The goal is to see if RFA is a good alter…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Prehab before cancer surgery may boost recovery
Symptom relief Recruiting nowThis study tests whether a program of targeted exercise and psychological support before cancer treatment (called prehabilitation) can help patients with solid tumors recover better physically and emotionally. Researchers will compare this program to standard care in 125 adults w…
Phase: NA • Sponsor: Priv.-Doz. Dr. med. Philipp Lenz • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Virtual reality goggles ease pain for kids with cancer
Symptom relief Recruiting nowThis study tests whether using a virtual reality helmet during painful medical procedures (like needle sticks or bone marrow tests) can reduce pain in children with cancer. About 74 children aged 6 to 18 will be split into two groups: one gets standard care plus the VR helmet, th…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Birthmark removal may boost Kids' Well-Being, study hopes to prove
Symptom relief Recruiting nowThis study looks at children with congenital melanocytic nevi (large birthmarks) who choose to have them surgically removed. Researchers want to see if removal improves quality of life and reduces feelings of being stigmatized. About 100 children aged 9 months to 16 years will be…
Sponsor: University Children's Hospital, Zurich • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New 'Lattice' radiation aims to zap tumor pain better than standard therapy
Symptom relief Recruiting nowThis phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Gentle movement method tested for kids with muscle disease
Symptom relief Recruiting nowThis study looks at whether the Alexander technique, a method that teaches better posture and movement habits, can help children aged 5 to 9 with Duchenne muscular dystrophy control their upper limbs and feel better day-to-day. About 33 kids will take part, and researchers will m…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Sensory play may ease autism symptoms in kids
Symptom relief Recruiting nowThis study tests whether sensory exercises can improve repetitive behaviors, communication, social interaction, and motor skills in children with autism. About 26 children aged 5 to 11 will take part. Researchers will measure changes using standard questionnaires before and after…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Can a cream stop cancer Treatment's ugly side effect?
Symptom relief Recruiting nowThis study tests whether a cream containing tretinoin (a form of vitamin A) can prevent or reduce the acne-like rash that often occurs in patients taking certain cancer drugs. About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo …
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Can we spot cancer before it starts? a massive study aims to find out
Knowledge-focused Recruiting nowThis study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Scientists hunt for better ways to spot hidden adrenal tumors
Knowledge-focused Recruiting nowThis study aims to improve how doctors find and understand pheochromocytomas and paragangliomas, rare tumors that can cause dangerous high blood pressure. Researchers will use advanced imaging scans and genetic testing in up to 3,000 participants to learn more about these tumors.…
Phase: PHASE1 • Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
New study aims to unlock secrets of rare cholesterol diseases
Knowledge-focused Recruiting nowThis natural history study is observing up to 250 people with Smith-Lemli-Opitz syndrome and related cholesterol disorders, as well as their relatives. Researchers will track symptoms, development, and lab results over several years to find better ways to measure disease progress…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Scientists hunt for genetic clues behind childhood pituitary tumors
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Cancer data pooling study aims to connect the dots across trials
Knowledge-focused Recruiting nowThis study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Could your genes raise your melanoma risk? new study seeks answers
Knowledge-focused Recruiting nowThis study aims to understand how genetics and environmental factors contribute to melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma or related conditions. Participants will fill out questionnaires, provide b…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Scientists launch Long-Term study to unravel mysterious immune condition
Knowledge-focused Recruiting nowThis study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Can a new questionnaire give patients a stronger voice in vascular malformation care?
Knowledge-focused Recruiting nowThis study aims to develop a standardized questionnaire that lets patients with venous malformations report their own symptoms and treatment outcomes. Venous malformations are abnormal veins that can cause pain, swelling, and emotional distress, and current assessments may miss w…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a nudge in your chart unlock Life-Saving genetic clues?
Knowledge-focused Recruiting nowThis study tests whether simple reminders—called nudges—sent to doctors and patients can increase the use of genetic testing for people with certain conditions like Parkinson's disease, ALS, or heart problems. The trial will compare different ways of prompting genetic testing, su…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Scientists track families to unlock secrets of inherited kidney cancer
Knowledge-focused Recruiting nowThis study follows families with a history of inherited kidney cancer to learn more about the disease's genetic causes and how it progresses. Researchers will collect blood, tissue, and urine samples from affected individuals and their relatives. The goal is to identify new genes…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New decision aid aims to empower advanced cancer patients in tough treatment talks
Knowledge-focused Recruiting nowThis study is creating a decision aid called TA-DA to help people with advanced cancer talk with their doctors about whether to try more treatments after several have already failed. The tool is designed to support shared decision-making. Researchers will test it with 155 patient…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New cancer Drug's interaction with other meds under scrutiny in early trial
Knowledge-focused Recruiting nowThis early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…
Phase: PHASE1 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Tumor DNA mapping may unlock personalized cancer therapies
Knowledge-focused Recruiting nowThis study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…
Phase: NA • Sponsor: Ulrik Lassen • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Scientists hunt for genetic clues in bladder cancer samples
Knowledge-focused Recruiting nowThis study collects blood, urine, saliva, and tumor tissue from 500 adults with urothelial cancer (bladder, ureter, or urethra) and healthy volunteers. Researchers will analyze the samples to find genetic differences between normal and cancer cells. The goal is to better understa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New model could make thyroid surgery safer and more predictable
Knowledge-focused Recruiting nowThis study aims to improve a prediction model that helps doctors know how difficult a less invasive thyroid surgery might be. Researchers will observe 300 people with thyroid cancer or benign nodules to see which factors, like age, weight, and tumor size, affect surgery difficult…
Sponsor: Shanghai 6th People's Hospital • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists hunt for gene behind rare kidney cancer syndrome
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of hereditary leiomyomatosis renal cell cancer (HLRCC), a condition that can lead to painful skin bumps, uterine fibroids, and kidney tumors. Researchers will study people with known or suspected HLRCC and their family members to iden…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Scientists launch massive tumor repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can modern Radiotherapy's late effects be predicted?
Knowledge-focused Recruiting nowThis study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Dietary change explored as cancer support strategy
Knowledge-focused Recruiting nowThis early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…
Phase: EARLY_PHASE1 • Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Reading Cancer's genetic playbook: a quest to match patients to the right experimental therapy
Knowledge-focused Recruiting nowThis observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
Knowledge-focused Recruiting nowThis trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Ultrasound after a first c-section may reveal hidden scar risks
Knowledge-focused Recruiting nowThis study uses transvaginal ultrasound to examine the uterine scar in women who have had a single cesarean section. Researchers aim to identify factors linked to a condition called a 'niche'—a small pocket in the scar that can cause symptoms like pelvic pain or abnormal bleeding…
Sponsor: Medical University of Gdansk • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
AI heart test may spot hidden danger in older cancer surgery patients
Knowledge-focused Recruiting nowThis study will enroll 200 adults aged 60 or older who are scheduled for major surgery for urologic cancer. Researchers want to see if an artificial intelligence analysis of a standard heart test (ECG) taken before surgery can predict whether a patient will suffer heart injury or…
Sponsor: Korea University Anam Hospital • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Massive HHT registry aims to unlock secrets of rare bleeding disorder
Knowledge-focused Recruiting nowThis study creates a large registry of people diagnosed with hereditary hemorrhagic telangiectasia (HHT), a condition causing abnormal blood vessels and bleeding. Researchers will collect medical records and annual health updates for up to 10 years to understand how the disease c…
Sponsor: Cure HHT • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
GPS for surgeons: navigation tech aims to simplify cancer lymph node removal
Knowledge-focused Recruiting nowThis study tests two navigation systems—3D Slicer and Siemens Monaco—to help surgeons locate and remove abnormal lymph nodes during urologic cancer surgery. The goal is to see if these image-guided tools make the procedure simpler and more precise. Twenty adults with suspected or…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Tiny study peers inside brain after AVM surgery
Knowledge-focused Recruiting nowThis study will follow 10 adults with unruptured brain arteriovenous malformations (AVMs) who are scheduled for surgery. Researchers will use special brain scans to measure blood flow and energy use in different brain regions before and six months after the operation. The goal is…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Could a cancer drug quiet overactive adrenal hormones? a new study investigates.
Knowledge-focused Recruiting nowThis pilot study looks at how belzutifan, a drug already used for some tumors, changes the production of adrenaline-like hormones in people with pheochromocytoma and paraganglioma (PPGL). Over 5 days, researchers measure key substances in the hormone-making process to see if belz…
Phase: PHASE2 • Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New approach aims to make repeat radiation safer for cancer patients
Knowledge-focused Recruiting nowThis study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Thousands of cancer patients enrolled in massive immunotherapy observation study
Knowledge-focused Recruiting nowThis study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can your mood impact pancreatic cancer survival?
Knowledge-focused Recruiting nowThis study looks at how ongoing stress, anxiety, and poor sleep might affect the course of pancreatic cancer. Researchers will ask 320 participants to fill out simple questionnaires about their mental well-being and will also measure stress markers in leftover blood samples. The …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Gene-Guided cancer therapy: a new hope for advanced tumors?
Knowledge-focused Recruiting nowThis study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…
Sponsor: Seoul National University Bundang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
770 cancer patients join study to unlock immunotherapy secrets
Knowledge-focused Recruiting nowThis study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could spinal anesthesia cut bleeding risk in prostate surgery?
Knowledge-focused Recruiting nowThis study compares spinal anesthesia to general anesthesia in men undergoing open simple prostatectomy for an enlarged prostate. The goal is to see if spinal anesthesia leads to less postoperative bleeding, such as fewer blood transfusions or less need for bladder irrigation. Ei…
Phase: NA • Sponsor: Hitit University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Leftover surgery tissue could unlock secrets of hardening arteries and bones
Knowledge-focused Recruiting nowThis study uses leftover tissue from heart and orthopedic surgeries to learn more about how calcification (hardening) happens in bones and blood vessels. Researchers will grow cells from these tissues in the lab to study the process. The goal is to better understand the disease, …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe immune resistance in tumors to outsmart cancer
Knowledge-focused Recruiting nowThis study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood biopsy study aims to improve cancer detection and monitoring
Knowledge-focused Recruiting nowThis study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New PET tracer could light up tumors for better cancer imaging
Knowledge-focused Recruiting nowThis early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Massive 15-year study launched to crack the code on rare brain-spine vessel disease
Knowledge-focused Recruiting nowThis study is a large registry that will collect data from over 10,000 people in China diagnosed with a rare condition where abnormal connections form between arteries and veins in the brain or spine. Researchers will track how common the disease is, what treatments are used, and…
Sponsor: Xuanwu Hospital, Beijing • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Gut bacteria linked to cancer survivor symptoms?
Knowledge-focused Recruiting nowThis study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
10,000 cancer patients join ontario Gene-Mapping effort to personalize care
Knowledge-focused Recruiting nowThis study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Brain surgery aftermath: new study tracks fluid leak risks
Knowledge-focused Recruiting nowThis study watches 200 adults having brain tumor surgery to see how often cerebrospinal fluid leaks happen and what makes them more likely. The goal is to find ways to prevent leaks and help people recover faster. No new treatment is being tested—just careful observation.
Sponsor: Medical University of Warsaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Stitch showdown: which scalp closure heals best after brain tumor surgery?
Knowledge-focused Recruiting nowThis study compares two common methods of closing the skin after brain tumor surgery: a continuous stitch under the skin using absorbable thread versus separate stitches through the skin using non-absorbable thread. Researchers want to see which method leads to fewer wound proble…
Phase: NA • Sponsor: Medical University of Warsaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
AI maps brain blood flow to supercharge aneurysm treatments
Knowledge-focused Recruiting nowThis study aims to make brain aneurysm and AVM treatments safer and more effective by using computer models and artificial intelligence. Researchers will create detailed maps of each patient's brain blood vessels and simulate blood flow to help doctors plan procedures. The study …
Sponsor: University Hospital, Ghent • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Personalized cancer care: DNA profiling guides patients to best trials
Knowledge-focused Recruiting nowThis study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can Off-Label drugs help when standard cancer therapy fails? new study aims to find out
Knowledge-focused Recruiting nowThis study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Scientists investigate adrenal tumors and seek better therapies
Knowledge-focused Recruiting nowThis study aims to learn more about how adrenal tumors form and to test new treatment options for adrenal cancer. Researchers will study up to 500 adults who have an adrenal tumor seen on imaging. The goal is to improve understanding and find better ways to treat these tumors.
Sponsor: University of Wuerzburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New scoring system could rate robot thyroid surgeons
Knowledge-focused Recruiting nowThis study aims to create and test a scoring system called RTAS to evaluate how well surgeons perform robotic thyroidectomy, a surgery to remove all or part of the thyroid gland. Researchers will observe 200 participants with thyroid cancer or benign nodules who are having this s…
Sponsor: Shanghai 6th People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Why does stroke cause chronic pain? new brain study seeks answers
Knowledge-focused Recruiting nowThis study looks at why some stroke survivors develop long-term pain called central poststroke pain (CPP). Researchers will use brain scans to see how brain connections change in people with CPP. The goal is to better understand what causes this pain, which could lead to better t…
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Which IV fluid works best during surgery? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at how well different fluids (albumin and Ringer's solution) increase blood volume during laparoscopic surgery. About 60 adults having abdominal surgery will receive one of three fluid types. The goal is to see which fluid keeps the heart and blood vessels workin…
Phase: PHASE4 • Sponsor: Joachim Zdolsek • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:27 UTC
-
Blood particles may predict chemo nerve pain
Knowledge-focused Recruiting nowThis study is testing whether tiny particles in the blood, called extracellular vesicles, can predict nerve damage caused by chemotherapy. Researchers will follow 120 adults with various cancers who are receiving specific chemo drugs. Participants give blood samples and answer qu…
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New study tracks Real-World care for sinonasal and Skull-Base tumours
Knowledge-focused Recruiting nowThis study is observing 120 patients with sinonasal or skull-base tumours at a specialist ear, nose, and throat centre. Researchers are tracking how these conditions are managed, what the outcomes are, and how patients' quality of life changes. The goal is to better understand cu…
Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Scientists dive deep into colorectal tissue to uncover cancer clues
Knowledge-focused Recruiting nowThis study looks at the immune cells and bacteria in colorectal tissue from people with benign or early-stage malignant growths. Researchers want to understand how the tissue environment changes as cancer develops. No treatments are tested; the goal is to gather information that …
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for hidden clues to stop spreading stomach cancer
Knowledge-focused Recruiting nowThis study aims to discover new ways to treat stomach cancer that has spread to other parts of the body. Researchers will collect tumor tissue, blood, and fluid samples from 100 patients to analyze their genes and proteins. The goal is to identify better treatment targets and tes…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists launch global effort to unravel mysteries of rare lymphatic diseases
Knowledge-focused Recruiting nowThis study is creating a registry of up to 1,000 people with rare lymphatic system disorders. Researchers will collect information from medical records and yearly surveys to understand how these diseases progress, what treatments are used, and how they affect quality of life. The…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can combining two Egg-Freezing methods help cancer patients preserve fertility?
Knowledge-focused Recruiting nowThis study looks at two ways to help cancer patients preserve their fertility before treatments like chemotherapy. One group will freeze both ovarian tissue and eggs, while the other group will freeze only eggs. Researchers will compare how many eggs are retrieved in each group. …
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can a simple score predict ICU need after cancer surgery?
Knowledge-focused Recruiting nowThis study looks at 500 adults having cancer surgery to see which risk scoring system best predicts if they'll need intensive care afterward. Doctors will calculate scores like ASA and SORT from patient data before and during surgery. The goal is to find the most accurate tool to…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
AI eye spots hidden blood vessels during surgery
Knowledge-focused Recruiting nowThis study tests an artificial intelligence tool that helps doctors see blood vessels during endoscopic procedures for achalasia or tumors. The AI aims to reduce the risk of bleeding and injury by spotting vessels faster and more accurately. Twenty participants will be enrolled t…
Phase: NA • Sponsor: Asian Institute of Gastroenterology, India • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
AI translates doctor speak for cancer patients
Knowledge-focused Recruiting nowThis study tests whether using artificial intelligence (AI) to rewrite medical discharge letters into plain language helps cancer patients better understand their diagnosis, treatment, and next steps. About 150 adults with blood cancer or other cancers will be randomly assigned t…
Phase: NA • Sponsor: Technical University of Munich • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists probe blood vessel role in skin disorders
Knowledge-focused Recruiting nowThis study looks at how abnormal blood vessel growth (angiogenesis) contributes to various skin diseases like rosacea, psoriasis, and certain tumors. Researchers will collect skin samples from 85 volunteers aged 16 and older to analyze markers of angiogenesis. The goal is to bett…
Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Cancer experts unite to personalize treatments in massive new study
Knowledge-focused Recruiting nowThis study enrolls up to 10,000 adults with cancer to see how a special team of experts (a molecular tumor board) uses genetic testing to recommend personalized treatments. Researchers will track whether doctors follow these recommendations and if patients benefit. The goal is to…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart hole linked to stroke risk in lung clot patients?
Knowledge-focused Recruiting nowThis study looks at whether people who have a blood clot in the lungs (pulmonary embolism) are more likely to have a stroke if they also have a small hole in their heart (called a PFO). About 1 in 4 people have this hole, which can let a clot travel to the brain. Researchers will…
Sponsor: Tufts Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Massive study aims to predict brain surgery success
Knowledge-focused Recruiting nowThis study is gathering information from 4500 people who have or will have brain surgery for conditions like aneurysms, tumors, epilepsy, and Parkinson's disease. The goal is to find patterns that help doctors predict how well someone will recover. By standardizing how outcomes a…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
15,000 cancer patients join radiation therapy registry to improve future care
Knowledge-focused Recruiting nowThis study is collecting medical data and biological samples from 15,000 people receiving radiation therapy for solid tumors or blood cancers. Researchers aim to understand how radiation affects quality of life, side effects, and survival. The goal is to learn from real-world out…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Could a simple Height-Based adjustment make tumor ablation safer?
Knowledge-focused Recruiting nowThis study looks at how to set the breathing machine (jet ventilator) during a procedure that destroys tumors with heat or cold. The goal is to find the best air pressure setting to keep patients breathing well while the doctor works precisely. About 560 adults having tumor ablat…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
1,000 patients to be tracked after brain and spine procedures – no new drug, just data
Knowledge-focused Recruiting nowThis study will follow 1,000 people of all ages who are having endovascular procedures (minimally invasive treatments through blood vessels) for brain or spinal conditions like aneurysms or abnormal blood vessels. Researchers will record complications, recovery, and changes in th…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Sweat sensor may predict blood pressure danger in elderly cancer surgery
Knowledge-focused Recruiting nowThis study is testing whether measuring skin conductance—a sign of nervous system activity—can predict dangerous drops in blood pressure after spinal anesthesia in elderly cancer patients. Researchers will monitor 102 patients aged 65 and older undergoing urologic cancer surgery.…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New registry to monitor ion beam therapy results
Knowledge-focused Recruiting nowThis registry study is collecting data from 2,800 cancer patients treated with ion beam therapy (protons and carbon ions) at MedAustron. Researchers will track tumor response, survival, side effects, and quality of life over time. The goal is to better understand the real-world b…
Sponsor: EBG MedAustron GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
8,000-Patient study aims to perfect Scope-Based cancer prevention
Knowledge-focused Recruiting nowThis study follows 8,000 people who are having precancerous or early cancerous growths in their digestive tract removed using a scope (endoscope). The goal is to see how often the procedure completely removes the lesion and to track any complications like bleeding or infection. B…
Sponsor: California Pacific Medical Center Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Lab-Grown tumor avatars could pick the right cancer drug for each patient
Knowledge-focused Recruiting nowThis study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Cancer Patients' samples fuel future discoveries
Knowledge-focused Recruiting nowThis research study collects blood and tissue samples from 20,000 people with suspected solid tumors. The samples are stored in a repository for scientists to study later. The goal is to advance our understanding of cancer, not to test a new treatment.
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Blood samples sought to build immune cell lab tool
Knowledge-focused Recruiting nowThis study collects blood samples from 1,500 adults, including cancer patients, healthy volunteers, and COVID-19 donors. Researchers aim to develop a device that can grow, select, and test immune cells (T cells) from the blood. The goal is to see if these cells can be trained to …
Sponsor: BioCytics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
AI predicts success of heat treatment for thyroid lumps
Knowledge-focused Recruiting nowThis study looks at how well ultrasound-guided heat ablation works for non-cancerous thyroid nodules and aims to create an AI model that can predict treatment results. Researchers will follow 1500 adults who choose this minimally invasive procedure instead of surgery. The goal is…
Phase: NA • Sponsor: Chinese PLA General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Scientists hunt for immune clues in rare salivary gland cancers
Knowledge-focused Recruiting nowThis study is for 300 people with salivary gland tumors (both cancerous and non-cancerous) to learn how the immune system reacts to these rare cancers. Researchers will collect tumor tissue and blood samples before and after treatment to find immune markers that might predict how…
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
500 kids on life support: China's decade of ECMO revealed
Knowledge-focused Recruiting nowThis study looks back at the past 10 years to understand how a life-support machine called ECMO has been used in children across China. Researchers will gather information from 500 children, from newborns to 18-year-olds, to see how many survive after treatment, how long they nee…
Sponsor: Children's Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study tracks pregnancy dangers in rare vascular conditions
Knowledge-focused Recruiting nowThis study follows 400 pregnant women with rare blood vessel diseases (like HHT, Marfan syndrome, or lymphedema) to learn about serious pregnancy complications. Researchers will ask participants about their health during pregnancy and for 12 months after birth. The goal is to gat…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Major study launches to unravel risks of birthmarks
Knowledge-focused Recruiting nowThis study follows 819 children under 2 years old who have medium to giant congenital nevi (pigmented birthmarks). Researchers will track neurological development, melanoma risk, and quality of life over time. The goal is to create better monitoring and treatment guidelines for t…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Cancer patients needed to help build massive research database
Knowledge-focused Recruiting nowThis study is creating a large registry and collection of blood, urine, and tumor samples from people with cancer or benign tumors who are receiving radiation therapy. The goal is to gather health information and biological samples for future research. Anyone 18 or older with a c…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Hysterectomy tool may impact sex life – new study investigates
Knowledge-focused Recruiting nowThis study looks at whether using a uterine manipulator during hysterectomy changes sexual function three months after surgery. Sixty women having a hysterectomy for non-cancer reasons will be randomly assigned to have the surgery with or without the tool. The main goal is to com…
Phase: NA • Sponsor: Erkan Gol • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New app aims to catch radiation side effects early
Knowledge-focused Recruiting nowThis study is testing a web-based application that lets cancer patients report side effects from radiation therapy in real time. The goal is to see if this tool helps doctors spot and address complications sooner. About 30 patients with gynecologic, urologic, or breast cancer wil…
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Simple blood test could catch cancer recurrence sooner
Knowledge-focused Recruiting nowThis study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning earlier than standard scans. About 100 people with different solid tumors will give blood samples after treatment. The goal is to see if early detection can lead to better treatm…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Blood tests could predict cancer therapy success
Knowledge-focused Recruiting nowThis study looks for proteins and other markers in the blood of 2000 adults with or suspected of having cancer. The goal is to find markers that may help doctors confirm a cancer diagnosis, choose the right treatment, and predict how well a patient will respond or if the cancer w…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC